Kovanaze, the first FDA-approved no-needle regional, pulpal anesthetic administered via nasal spray.
According to Zachary Kulsrud, Kovanaze provides regional, pulpal anesthesia with 96% efficacy in teeth Nos. 5–12, therefore Kovanaze offers a needle-free alternative to the majority of anterior maxillary injections.
Additionally, patients may not experience the same sensations of numbness or tingling of the lips and cheeks associated with injectable dental anesthetics.
Kovanaze is the first no-needle regional, pulpal anesthetic administered via nasal spray to be approved by the US Food and Drug Administration (FDA), and it offers patients a safe and effective, needle-free alternative to anesthetize teeth 4-13 for restorative dental procedures.
For more details, please contact our office at 561-832-4675.